OrbiMed’s Sage Therapeutics SAGE Stock Holding History

OrbiMed’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-36,300	Closed	-$3.48M	–	139
2018 Q4	$3.48M	Buy	+36,300	New	+$4.15M	0.06%	110
2016 Q4	–	Sell	-235,400	Closed	-$10.8M	–	139
2016 Q3	$10.8M	Buy	+235,400	New	+$9.58M	0.12%	99
2015 Q4	–	Sell	-149,999	Closed	-$6.35M	–	134
2015 Q3	$6.35M	Sell	149,999 -1	-0%	-$62	0.06%	106
2015 Q2	$10.9M	Sell	150,000 -262,335	-64%	-$16.9M	0.09%	101
2015 Q1	$20.7M	Hold	412,335	–	–	0.18%	78
2014 Q4	$15.1M	Sell	412,335 -125,000	-23%	-$4.66M	0.14%	84
2014 Q3	$16.9M	Buy	+537,335	New	+$15.6M	0.18%	82

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OrbiMed's SAGE Position: Q1 2019 in Review

OrbiMed sold out of Sage Therapeutics (SAGE) in Q1 2019, closing a stake of 36,300 shares — an estimated $3.48M sold.

OrbiMed first reported a position in SAGE in Q3 2014 and held it in 7 quarters. The position peaked at $20.7M in Q1 2015. 267 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

OrbiMed reported no remaining Sage Therapeutics position as of Q1 2019 after selling out during the quarter.
OrbiMed sold 36,300 Sage Therapeutics shares in Q1 2019, an estimated $3.48M.
OrbiMed first reported a position in Sage Therapeutics in Q3 2014 and held it in 7 quarters.
OrbiMed's Sage Therapeutics position peaked at $20.7M in Q1 2015.
267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.